Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

131

Participants

Timeline

Start Date

June 8, 2017

Primary Completion Date

September 29, 2023

Study Completion Date

September 29, 2023

Conditions

Alzheimer's Disease

Interventions

DRUG

icosapent ethyl (IPE)

Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo

OTHER

gel cap placebo

Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo

Trial Locations (1)

William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison

All Listed Sponsors

collaborator

University of Wisconsin, Madison

OTHER

lead

VA Office of Research and Development

FED

NCT02719327 - Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid | Biotech Hunter | Biotech Hunter